Cannabinoids for use in the treatment of neurodegenerative diseases or disorders

a neurodegenerative disease or disorder, cannabis technology, applied in the direction of biocide, cardiovascular disorder, drug composition, etc., can solve the problems of cell death or damage to genetic material, deterioration of the functions controlled by the affected part of the nervous system, cell membrane damage,

Active Publication Date: 2014-08-14
GW PHARMA LTD
View PDF1 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0054]The amount of non-phytocannabinoid containing component in the BDS may be less than 45%, through 40%, 35%, 30%, 25%, 20% to 15% or less of the total extract. The actual amount is likely to depend on the starting material used and the method of extraction used.
[0

Problems solved by technology

The damage or death of neurons leads to a gradual deterioration of the functions controlled by the affected part of the nervous system.
When levels of free radicals or other pro-oxidants increase to such an extent, they can cause damage to cell membranes which in turn may result in cell death or damage to genetic material.
The radicals cause disruption of essential reactions in the neurones and this leads to degeneration or death of the cell.
One drug Dextrorphan is of limited use however due to its side effects of hallucinations, agitation and hypotension.
Another drug,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
  • Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
  • Cannabinoids for use in the treatment of neurodegenerative diseases or disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

The Effects of Cannabinoids in a Model of Neurodegenerative Disease

Materials and Methods

[0068]The cannabinoids tested were CBG, CBC, and CBDV. The cannabinoids were isolated from cannabis plant material and purified. The cannabinoids were tested at a concentration of 10−9 to 10−6 M. The cannabinoids were dissolved in DMSO at the concentration of 10−2M and then diluted in DMEM to their final concentration.

[0069]Glial cells (C6) were cultured in 10% FBS supplemented DMEM. PC12 neuronal cell were cultured in 10% FBS plus 5% HS supplemented DMEM and SHY-5SY neuronal cells were cultured in 10% FBS supplemented RPMI. Neuronal cells were differentiated with retinoic acid. After 24 hours of starvation glial cells, differentiated PC12 and SHY-5SY neuronal cells were treated with the cannabinoids, CBC, CBG and CBDV, in the presence or absence of 1 μg / mL of Aβ (1-42) for the following 24 hours.

[0070]Cell viability was determined using 3(4,5-dimethylthiazol-2yl)2,5-diphenyl-2H-tetrazolium bromi...

example 2

The Neuroprotective Effects of Cannabidivarin (CBDV)

Materials and Methods

[0082]Glial cells (C6) were cultured in 10% FBS supplemented DMEM, and SHY-5SY were cultured in 10% FBS supplemented RPMI. Neuronal cells were differentiated with retinoic acid. After 24 hours of starvation glial cells and SHY-5SY were treated with CBDV (10−7M), CBD (10−7 M), CBDVA (10−7 M), CBDA (10−7 M) and THCVA (10−7 M) in presence or absence of Aβ (1-42) (1 μg / mL) for following 24 hours. All tested compounds were dissolved in DMSO at the concentration of 10−2 M and then diluted in DMEM; DMSO at final dilution that did not show any effects on the parameters under study.

[0083]Cell activation / viability was determined using 3(4,5-dimethylthiazol-2yl)2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, an assay based on the ability of viable cells to convert MTT in formazan salt. Briefly, the cells were plated in 96-well culture plates at the density of 5×103 cells / well and allowed to adhere at 37° C. for 2 hours. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.

Description

[0001]The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and / or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.BACKGROUND TO THE INVENTION[0002]Neurodegenerative diseases or disorders are caused by the progressive damage or death of neurons. Neurons are nerve cells in the brain whose primary function is to assist in the memory process. The damage or death of neurons leads to a gradual deterioration of the functions controlled by the affected part of the nervous system.[0003]Neurodegenerative diseases or disorders often occur as a result of oxidative stress. Oxidative stress occurs to the cells in an organism when the effects of pro-oxidants (such as free radicals, reactive oxygen and reactive nitrogen species) exceed the ability of anti-oxidan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/05
CPCA61K31/05A61K31/192A61K31/352A61P9/10A61P25/00A61P25/16A61P25/28A61K36/185
Inventor IUVONE, TERESADI MARZO, VINCENZOGUY, GEOFFREYWRIGHT, STEPHENSTOTT, COLIN
Owner GW PHARMA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap